Ticagrelor vs Clopidogrel in Non-ST Elevation Acute Coronary Syndrome Patients Undergoing PCI With Bivalirudin. (NSTE-ACS)
A Phase IV, Randomised, Multi-Centre, Open Label Study, Comparing Ticagrelor Versus Clopidogrel in Non-ST Elevation Acute Coronary Syndrome (NSTE-ACS) Patients Undergoing Percutaneous Coronary Intervention (PCI) With Bivalirudin
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Fase
Fase
- Fase 4
Kontakter og lokationer
Studiesteder
-
-
Florida
-
Jacksonville, Florida, Forenede Stater
- Research Site
-
Lake Mary, Florida, Forenede Stater
- Research Site
-
-
Georgia
-
Macon, Georgia, Forenede Stater
- Research Site
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Forenede Stater
- Research Site
-
-
Pennsylvania
-
Hershey, Pennsylvania, Forenede Stater
- Research Site
-
Philadelphia, Pennsylvania, Forenede Stater
- Research Site
-
Pittsburgh, Pennsylvania, Forenede Stater
- Research Site
-
-
South Dakota
-
Rapid City, South Dakota, Forenede Stater
- Research Site
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Hospitalised for chest pain and potential acute coronary syndrome.
- Onset of the most recent cardiac ischemic symptoms must occur within 7 days before randomisation and documented by cardiac ischemic symptoms of ≥ 10 min duration at rest and at least 2 of the following: ST segment changes on electrocardiogram (ECG) indicative of ischemia, or Positive biomarker evdience of myocardial necrosis, or other risk factors such as: 60 yrs of age or older, previous myocardial infarction or coronary bypass surgery, multi-vessel coronary artery disease, diabetes mellitus, peripheral arterial disease, chronic renal disfunction.
- Females must be either surgically sterile or post-menopausal.
- Activated Clotting Time (ACT) </= 300 at the time of study treatment
Exclusion Criteria:
- Participation in another clinical study with an investigational product during the last 30 days.
- Current acute complication of percutaneous coronary intervention or coronary bypass surgery.
- Any contraindication to ticagrelor, clopidogrel or bivalirudin.
- ST elevation myocardial infraction within 24 hours of study entry.
- Any indications for oral anticoagulation or aspirin dose other than 75 to 100 milligrams (mg) daily.
- Planned use of omeprazole or esomeprazole.
- Patients with known bleeding or coagulation disorders; patients requiring dialysis; patients who have an inability to swallow medication.
- Patients with known bleeding diathesis or coagulation disorder; history of intracranial bleed.
- Use of Intravenous (IV) heparin less than 2 hours before procedure.
- Sustained uncontrolled high blood pressure
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Ticagrelor
90 mg oral tablet
|
Single loading dose of 180mg of ticagrelor at time of bivalirudin administration.
Beginning 12 hrs following study drug administration, all pts in the ticagrelor arm will receive ticagrelor 90 mg (maintenance dose) approximately every 12 hrs until Follow-up telephone contact.
Andre navne:
|
|
Aktiv komparator: Clopidogrel
300 mg oral tablet
|
Single loading oral dose of 600 mg of clopidogrel will be given at time of bivalirudin administration.
Beginning 4 hrs following study drug administration, all pts in the clopidorgrel arm will receive ticagrelor 180 mg for the loading dose, followed by 90 mg maintenance dose approximately every 12 hours until the Follow-up telephone contact.
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
P2Y12 Reaction Units (PRU) Using VerifyNow™ at 0.5 Hours After Loading Dose
Tidsramme: 0.5 hours post loading dose
|
PRU at 0.5 hours after a single oral loading dose of either ticagrelor 180 mg or clopidogrel 600 mg given at the time of the bivalirudin bolus
|
0.5 hours post loading dose
|
|
P2Y12 Reaction Units (PRU) Using VerifyNow™ at 1 Hour After Loading Dose
Tidsramme: 1 hour post loading dose
|
PRU at 1 hour after a single oral loading dose of either ticagrelor 180 mg or clopidogrel 600 mg given at the time of the bivalirudin bolus
|
1 hour post loading dose
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Ledende efterforsker: Marc Cohen, MD, Newark Beth Israel Medical Center
Datoer for undersøgelser
Studer store datoer
Studiestart
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Faktiske)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Patologiske processer
- Myokardieiskæmi
- Hjertesygdomme
- Hjerte-kar-sygdomme
- Karsygdomme
- Sygdom
- Syndrom
- Akut koronarsyndrom
- Lægemidlers fysiologiske virkninger
- Neurotransmittermidler
- Molekylære mekanismer for farmakologisk virkning
- Blodpladeaggregationshæmmere
- Purinerge P2Y-receptorantagonister
- Purinerge P2-receptorantagonister
- Purinerge antagonister
- Purinerge midler
- Ticagrelor
- Clopidogrel
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- D5130L00065
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .